0000899243-20-023341.txt : 20200824
0000899243-20-023341.hdr.sgml : 20200824
20200824210956
ACCESSION NUMBER: 0000899243-20-023341
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200820
FILED AS OF DATE: 20200824
DATE AS OF CHANGE: 20200824
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nielsen Jack
CENTRAL INDEX KEY: 0001602402
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39450
FILM NUMBER: 201129296
MAIL ADDRESS:
STREET 1: C/O AKEBIA THERAPEUTICS, INC.
STREET 2: 245 FIRST STREET, SUITE 1100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc.
CENTRAL INDEX KEY: 0001802665
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822279923
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 630 W GERMANTOWN PIKE
STREET 2: SUITE 215
CITY: PLYMOUTH MEETING
STATE: PA
ZIP: 19462
BUSINESS PHONE: (484) 539-9800
MAIL ADDRESS:
STREET 1: 630 W GERMANTOWN PIKE
STREET 2: SUITE 215
CITY: PLYMOUTH MEETING
STATE: PA
ZIP: 19462
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-20
0
0001802665
Harmony Biosciences Holdings, Inc.
HRMY
0001602402
Nielsen Jack
C/O 630 W. GERMANTOWN PIKE, SUITE 215
PLYMOUTH MEETING
PA
19462
1
0
0
0
Common Stock
2020-08-20
4
P
0
2736
35.00
A
2736
I
See Footnote
Common Stock
2020-08-21
4
P
0
24812
24.00
A
27548
I
See Footnote
Common Stock
2020-08-21
4
P
0
7352
34.10
A
34900
I
See Footnote
Common Stock
2020-08-24
4
P
0
3057
34.30
A
37957
I
See Footnote
The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.
The price reported herein is the public offering price.
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $33.3 to $35.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $35.0 to $33.8, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
/s/ Stephanie Wisdo, Attorney-in-fact for Jack Bech Nielsen
2020-08-24